Control
Jan 14 2022 |
et al., International Journal of Molecular Medicine, doi:10.3892/ijmm.2022.5084 | Efficacy of the use of mefenamic acid combined with standard medical care vs. standard medical care alone for the treatment of COVID‑19: A randomized double‑blind placebo‑controlled trial |
| 94% improved recovery (p=0.03). RCT 36 COVID-19 outpatients showing reduced time to an "acceptable symptom state" with mefenamic acid treatment, however the effect was driven by pain-related symptoms and is likely, at least in part, due to mefenamic acid’s ana.. | ||